Anupam Rasayan Acquires Stake in Bliss GVS Pharma in Strategic Move to Build Integrated Pharma Platform

Anupam Rasayan Acquires Stake in Bliss GVS Pharma in Strategic Move to Build Integrated Pharma Platform​

Anupam Rasayan India Ltd., a prominent provider of custom synthesis and specialty chemicals, announced on May 23, 2026, that it has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake, along with an Open Offer to the public shareholders, of Bliss GVS Pharma Limited.

The acquisition targets Bliss GVS Pharma Limited, an India-based pharmaceutical formulations company.

The total purchase consideration for the acquisition has been structured through a combination of financing sources:

• Rs 300 Crores via a Term Loan.
• Non-controlling non-voting equity instrument for the remaining amount.

Understanding Bliss GVS Pharma​

Bliss GVS Pharma Limited is a company specializing in the development, manufacturing, marketing, and export of a wide range of dosage forms. Its portfolio includes suppositories, pessaries, tablets, capsules, syrups, injectables, creams, and ointments. Established in 1984, the company has established a strong presence across international markets, particularly in Africa, Asia, and Latin America.

The company is recognized globally for its leadership in suppositories and pessaries, boasting one of the largest product portfolios in this segment and holding certifications like US FDA, WHO-GMP, and EU-GMP. Bliss GVS Pharma maintains a diversified portfolio of over 150 branded formulations across therapeutic areas such as anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, and women's healthcare. Key brands in its portfolio include Lonart, PAlaxin, Funbact, and Lofnac.

Bliss GVS Pharma operates multiple manufacturing facilities in Maharashtra and Daman and continues to expand its R&D, manufacturing, and international marketing footprint.

Synergies and Strategic Outlook​

Commenting on the transaction, Mr. Anand Desai, Managing Director of Anupam Rasayan India Ltd., stated that the agreement marks a crucial milestone in Anupam Rasayan's vision to build an integrated global life sciences and specialty pharmaceutical platform.

He noted that this acquisition will strategically strengthen Anupam Rasayan's presence across the pharmaceutical value chain, encompassing KSMs (Key Starting Materials) to finished dosage formulations. Mr. Desai further elaborated that combining Anupam Rasayan's advanced chemistry capabilities with Bliss GVS Pharma's well-established capabilities in niche dosage forms, strong international footprint, and differentiated brands will create a broader, integrated, and diversified pharmaceutical manufacturing ecosystem.

This combined platform is expected to enhance global reach, especially in the Europe and America market, and is anticipated to unlock significant synergies through expanded product offerings, improved customer engagement, and accelerated innovation across both regulated and semi-regulated markets.

About Anupam Rasayan India Limited​

Anupam Rasayan India Ltd. is a leading specialty chemicals major engaged in custom synthesis (CSM) and manufacturing. The company, incorporated in 1984, operates with two core verticals: Life science related Specialty Chemicals (including products for Agrochemicals, Personal Care, and Pharmaceuticals) and Other Specialty Chemicals (including Polymer Additives). Anupam caters to a diverse base of Indian and global customers and operates via eight manufacturing facilities. As of March 31, 2026, the company had an aggregate installed capacity of over 2,00,000 MT.

ANURAS Stock Price Movement​

Anupam Rasayan India Limited shares slipped by 1.11% on Friday, settling at ₹1366.1 before the market closed. The equity saw significant turnover, trading a total volume of 389,512 shares during the session.